No Data
No Data
Zhejiang Hisun Pharmaceutical: Give up the pharmaceutical distribution raw material business, leading to a decline in H1 revenue. Sales of Olsalazine increased significantly compared to the same period last year.
①At the earnings conference, the CFO of Zhejiang Hisun Pharmaceutical explained that the decline in H1 revenue was due to the company's abandonment of low-margin pharmaceutical distribution raw material business and other factors. ②President Xiao Weihong addressed questions about the growth in endocrine drug revenue and the future business model of the animal health sector.
Zhejiang Hisun Pharmaceutical Co., Ltd. 2024 Interim Report
Summary of Zhejiang Hisun Pharmaceutical Co., Ltd.'s 2024 interim report.
Zhejiang Hisun Pharmaceutical (600267.SH): net income of 4.35 billion yuan in the first half of the year, a year-on-year growth of 7.7%.
On August 19, GeLongHui reported that Zhejiang Hisun Pharmaceutical (600267.SH) released its semi-annual report, achieving revenue of 5.24 billion yuan, a decrease of 13.48% year-on-year, and net profit attributable to owners of the parent company of 435 million yuan, a year-on-year increase of 7.70%. Net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 259 million yuan, a year-on-year decrease of 7.95%. The increase in net profit attributable to the parent company was mainly due to cost savings and increased investment income during the period. Founded in 1956, after more than 60 years of development, Zhejiang Hisun Pharmaceutical has become a company that integrates research, development, production, sales, and the full value chain of active pharmaceutical ingredients and formulations.
Hisun Pharmaceutical Gets Nod to Market Eltrombopag; Shares Up 3%
Zhejiang Hisun Pharmaceutical (600267.SH): The active pharmaceutical ingredient of Apremilast obtains the Approval of Listing Application for Chemical Raw Materials.
On August 5th, Gelunhui reported that Zhejiang Hisun Pharmaceuticals Co., Ltd. (600267.SH) has received the "Chemical raw materials for Apixaban Ethanolamine" market approval application approval letter issued by the National Medical Products Administration on August 5, 2024. Apixaban Ethanolamine is indicated for use in adult and pediatric (6 years and older) chronic immune thrombocytopenia (ITP) patients who have responded poorly to glucocorticoids, immunoglobulins, and other therapies and who have increased risk of bleeding due to decreased platelet count. It increases platelet counts and reduces or prevents bleeding, and is only used for ITP patients at risk of bleeding caused by decreased platelet count and clinical conditions.
No Data
No Data